Symphony Health, the data solutions division of global contract research organization (CRO) PRA Health, will work with Close-Up International, a medical prescription and sales audits provider, to bring forward products, services, and solutions to the pharmaceutical industry.
The former company connects clients to primary and secondary data to deliver clients with an understanding of disease incidence, prevalence, progression, treatment and influences through the patient journey.
Doug Fulling, president of Symphony Health, said in a statement that the agreement demonstrates the company’s aim to expand internationally. Per the agreement, the organizations will exclusively distribute one another’s retail and non-retail data in their respective geographies.
“Close-Up is in a leadership position in the Latin American market – they were the creators of the first medical prescription audit in the world and have continued to innovate. Working with Close-Up opens the Latin American market to our business and to our current and prospective clients who are doing business in that area of the world,” Fulling told us.
He said, “The presence across up to a dozen geographies adds a critical component to Symphony’s offerings that will build and strengthen relationships for both organizations in the US and Latin America. The data solutions and insights available through Symphony and Close-Up international will drive future drug development and commercialization strategies.”
Fulling told us that the strategic alliance with Close-Up is one of many that Symphony is working on, as it continues to extend its data solutions globally.
“Health care data solutions need to be agile, flexible, and adaptive to the patients and the clients that we serve,” Fulling said.
“Working with strategic partners like Close-Up allow PRA Health Sciences and Symphony Health to better track and understand patient populations all over the world, which allows our pharmaceutical and biotech clients, who work in global markets, to have data and insights at their fingertips,” he added.
The global CRO has been actively growing its footprint in multiple geographic locations; most recently, it bought out its joint venture with Takeda. PRA Health Sciences K.K. is now operating as a PRA subsidiary in Japan. With this buyout, PRA has new offices in Tokyo and Osaka and more than 2,300 staff members across 15 countries in the Asia region.